Cancer BiologybioRxiv
Exploiting KRAS-driven Ferroaddiction in Cancer Through Ferrous Iron-Activatable Drug Conjugates (FeADC)
H. Jiang, R. K. Muir, R. L. Gonciarz…·A. Renslo
This paper develops FeADCs, ferrous iron-activatable drug conjugates, to target KRAS-driven cancers with improved tumor selectivity and systemic tolerability.
DOI 10.1084/jem.20210739